Huatai Securities Injects $15M Into Chinese Genetic, Protein Engineering Tech Start-Up

Login to View

Abiochem Biotechnology Co Ltd, a Chinese biotech start-up specialized in genetic and protein engineering technologies, has raised over RMB100 million (US$14.89 million) in a new round of financing led by Huatai Zijin Investment, a wholly-owned investment subsidiary of Chinese securities group Huatai Securities, according to a statement released on Wednesday.

China Money Network

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech


Read 2 Articles for Free with a Basic Account

Gain limited and restricted access to China Money Network.

Register Basic Account

Subscribe for an annual subscription!

Enjoy comprehensive and exclusive data you can't find elsewhere!

More Info


Subscribe and Pay Easily Online!

Already have an account or paid subscription? Log in


RELATED NEWS